Our Business

Pfizer Innovative Health

Pfizer Innovative Health (PIH) includes six business groups – Consumer Healthcare, Inflammation & Immunology, Internal Medicine (neuroscience and pain, and cardiovascular and metabolic), Oncology, Rare Disease and Vaccines.

Each business group is committed to improving health with our innovative products from prevention to treatment to wellness – at every stage of life in communities across the globe. Our Emerging Markets group is focused on increasing access to Pfizer’s innovative portfolio of medicines to people across developing countries in Latin America, Asia, Africa and the Middle East. And, our Patient and Health Impact group develops solutions for increased patient access, demonstrates the value of our innovations and ensures broader business model innovation.

With our renewed mission and bold structure designed to amplify each group’s strengths, PIH is positioned to lead change for healthcare around the world. We’re not just discovering new medicines – we are driving the future of health care.

Consumer Healthcare

Pfizer is among the largest over-the-counter (OTC) health care companies in the world. Our brands are sold across more than 90 countries and help people take charge of their own health and wellness. Our trusted brands include Advil®, Caltrate®, Centrum®, ChapStick®, Emergen-C®, Preparation H®, Nexium® 24HR, Robitussin® and ThermaCare®.

By leveraging insights gleaned from consumer research, concept testing and product research, as well as by working closely with our retail partners, the Consumer Healthcare business is delivering products and solutions that anticipate consumers’ needs and fit their lifestyles. One example of our insights-driven approach in action is the introduction of Centrum VitaMints® as a new option for consumers who wanted an easy-to-take multivitamin that works with on-the-go lifestyles.

We’re also taking a broad view of how our expertise and innovation can benefit even more consumers, as we look to expand our impact beyond the $250 billion OTC market to the much broader $2.5 trillion health and wellness market and bring new, innovative solutions to consumers around the world.

Learn more about our Consumer Healthcare products and how they are driving health and wellness.

Inflammation & Immunology (I&I)

Pfizer is a global leader in developing medicines to help people with chronic immune and inflammatory diseases, and we leverage our long-standing scientific heritage to address the root causes of these conditions. We have a vast portfolio that includes new molecular entities under investigation in rheumatology, dermatology and gastrointestinal diseases. Our inline portfolio includes Xeljanz/Xeljanz® XR (tofacitinib citrate) for patients with rheumatoid arthritis and Enbrel® (etanercept) outside the U.S. and Canada for patients suffering from conditions such as rheumatoid arthritis and psoriasis.

In December of 2016, the United States (U.S.) Food & Drug Administration (FDA) approved Eucrisa (crisaborole) ointment, two percent, for the treatment of mild-to-moderate atopic dermatitis in adults and children two years of age and older. Eucrisa, which came to Pfizer through our acquisition of Anacor Pharmaceuticals, Inc., is a novel non-steroidal topical phosphodiesterase-4 (PDE-4) inhibitor and is the first prescription treatment for atopic dermatitis to receive FDA approval in more than a decade.

Neuroscience & Pain

Neurodegenerative diseases and their accompanying psychiatric symptoms are among the most devastating disorders, often robbing patients of their dignity, awareness and ability to conduct life’s most basic daily activities. By most estimates, neurologic diseases account for more disability and cost than any other disease category. Whether through the slow loss of memory and self in Alzheimer’s disease, the crippling loss of motor function in Parkinson’s disease or the change in mood and motivation that often accompanies these conditions, nervous system disorders present an enormous scientific and social challenge.

The brain is the root of our consciousness, emotions, language, memory, and movement, making it a scientific puzzle researchers are struggling to put together.

The brain is a complex organ with discreet and unique neuronal structures. It is the root of our consciousness, emotions, language, memory and movement, making it a scientific puzzle researchers are still struggling to put together. In recent years, scientists have uncovered new insights on the brain thanks to the decoding of the human genome, greater understanding of brain physiology, the application of a systems and circuitry approach, and more precise imaging technologies.

Time is of the essence as an aging population will only increase the burden of neurodegenerative diseases.1 More than 10 million people worldwide are already living with Parkinson’s disease, while another 46 million have Alzheimer’s or related dementias.2, 3 By midcentury, these figures could triple.4, 5

Learn more about how we are partnering to advance outcomes in a number of neurological conditions.

Learn more about how we are re-thinking treatment procedures for neurological disorders.

We continue to address the needs of patients living with different types of chronic pain – through our treatment portfolio and pipeline, and via innovative educational programs.

Pfizer and Eli Lilly and Company are currently studying tanezumab, an investigational nerve growth factor antibody, for the treatment of pain in patients with osteoarthritis, chronic low back pain and cancer pain. There are currently six Phase 3 studies in approximately 7,000 patients ongoing.

This year, Pfizer launched a pilot in Brazil and Mexico for a wearable device, called BeLive, which helps patients on Lyrica® (pregabalin) to better understand their chronic pain condition. The pilot program confirmed patients’ willingness to record their pain and associated symptoms on wearable wrist devices synchronized with their smartphones and demonstrated physician receptivity to wearable patient diaries rather than using paper diaries.

We also conducted the Community Health Perspectives survey in collaboration with the American Diabetes Association and supported by the National Medical Association to uncover barriers and gaps in the diagnosis and management of diabetic nerve pain among African Americans and Hispanic Americans. By shining a light on the disparities, our goals were awareness and education among people with diabetes experiencing symptoms of diabetic nerve pain and to encourage them to speak with a health care provider.

Cardiovascular & Metabolic Diseases

For more than 50 years, Pfizer has led the way in redefining the management of cardiovascular risk by bringing much-needed treatments to patients.

Today, Pfizer is focused on investigating potential cardiovascular disease therapies that treat both the metabolic abnormalities that increase the likelihood of cardiovascular disease and the heart itself by trying to alter the way it responds to the abnormal metabolic state. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients.

Our early discovery efforts focus on emerging areas of cardiovascular research such as control of eating disorders, type 2 diabetes/muscle uptake of glucose and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Pfizer has a robust pipeline that includes ertugliflozin, a SGLT-2 inhibitor being developed in collaboration with Merck & Co., Inc. for the treatment of type 2 diabetes as a monotherapy and in a fixed-dose combination with Merck's leading oral therapy Januvia® (sitagliptin).

Learn more about Pfizer’s partnerships to tackle non-communicable diseases (NCDs) like cardiovascular disease and diabetes.


As a leader in oncology, Pfizer is speeding cures and breakthrough medicines to patients, Pfizer is helping to redefine life with cancer. We have a strong oncology portfolio, including Ibrance® (palbociclib), Xtandi® (enzalutamide), and Xalkori® (crizotinib), as well as investigational assets utomilumab, lorlatinib, inotuzumab, avelumab (being developed in collaboration with Merck KGaA) and talazoparib.

In 2016, we continued our scientific and regulatory momentum in oncology. Pfizer’s Ibrance, which received initial FDA approval in early 2015 and expanded approval in early 2016, obtained approval from the European Medicines Agency in late 2016 for the treatment of women with HR+/HER2-locally advanced or metastatic breast cancer. The approval for Ibrance is to be used in combination with an aromatase inhibitor and also covers the use of Ibrance in combination with fulvestrant in women who have received prior endocrine therapy. In March 2016, the Xalkori supplemental new drug application was approved by the FDA, granting it an additional indication for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Additionally, August 2016 marked the fifth anniversary of the FDA approval of Xalkori, which was the first treatment approved for patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In addition, Xtandi demonstrated an improvement in radiographic progression in studies in patients with metastatic prostate cancer compared to patients treated with bicalutamide. We are also exploring expanded clinical applications for Xtandi, including in triple-negative breast cancer.

Learn more about these milestones and how our oncology portfolio is accelerating patient impact.

Learn more about our partnerships to advance immuno-oncology development.

Rare Disease

Rare Disease represents an important opportunity to apply Pfizer’s knowledge and expertise to help make a significant impact on addressing patients’ unmet medical needs. Pfizer has a dedicated research unit focusing on rare diseases and a global portfolio of medicines with a number of disease areas of focus including hematology, neuroscience and inherited metabolic disorders. We innovate every day through innovative strategic collaborations with academic researchers, patients and other companies that take advantage of our large global footprint.

Learn more about Pfizer's Rare Disease portfolio and how we empower patients, engage communities in our clinical development programs and support programs that heighten disease awareness and meet the needs of patient families.

Learn more about how Pfizer is harnessing the power of technology and innovation to advance care in rare disease.


Pfizer is dedicated to developing innovative vaccines for unmet medical needs throughout all stages of life and across all geographies. Our portfolio includes Prevnar/Prevenar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 Protein]) for pneumococcal disease, as well as Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine), Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine), Neisvac-C (meningococcal group C-TT conjugate vaccine, adsorbed) and Trumenba® (Meningococcal Group B Vaccine) for meningococcal meningitis, and FSME-Immun for tick-borne encephalitis (TBE). In our vaccines pipeline, we are evaluating several investigational therapies with a focus on healthcare-acquired infections and maternal health.

In 2016, the U.S. indication for Prevnar 13 was expanded to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). Prevnar 13 is also approved for children 6 weeks through 17 years of age (prior to the 18th birthday) for the prevention of invasive disease caused by the 13 strains of S. pneumoniae in the vaccine, and for children 6 weeks through 5 years (prior to the 6th birthday) for the prevention of ear infections caused by 7 of the 13 strains in the vaccine.

In addition to providing product donations when appropriate, Pfizer also announced a major expansion of its humanitarian assistance program, enabling broader access to Prevenar 13 in humanitarian emergency settings, by offering it at the lowest prevailing price (currently $3.05 per dose). In addition, given the acute need, we indicated we will donate all sales proceeds for the first year from this program to humanitarian groups undertaking the difficult work of reaching vulnerable populations facing humanitarian emergencies.

Learn more about our vaccines portfolio and how it is accelerating patient impact.


Niccoli T, Partridge L.

Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012 Sep 11;22(17):R741-52. doi: 10.1016/j.cub.2012.07.024.

Parkinson’s Disease Foundation

Parkinson’s Disease Foundation. Available on http://www.pdf.org/en/parkinson_statistics. Accessed on August 1, 2016.

World Alzheimer Report 2015

World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer’s Disease International (ADI), London.

Blennow K, de Leon MJ, Zetterberg H.

Blennow K, de Leon MJ, Zetterberg H. Alzheimer disease. Lancet. 2006;368(9533):387–403. Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch Neurol. 2008; 65(3):329–34. Available on http://www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.pdf Accessed on March 10, 2015.

Dorsey ER, Constantinescu R, Thompson JP, et al.

Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. Epub 2006 Nov 2.

How our work in this area is supporting the Sustainable Development Goals

Gender Equality

We seek to empower and mobilize women around the world through partnerships aimed at ensuring access to quality health care, including newborn immunizations and family planning services.

Partnerships for the Goals

Through innovative partnerships, including collaborations with non-governmental organizations (NGOs), governments, foundations, social entrepreneurs and colleagues, we seek to fuel creative approaches that accelerate progress and improve health care.